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there was no difference in contraction by endothelin. Evero-
limus did not alter the contractility response at all. In sum-
mary, norepinephrine-induced, but not endothelin-induced, 
contractile responses of mesenteric resistance arteries are 
blunted in CsA-treated rats. This finding was accompanied 
by a marked downregulation of adrenoreceptors in mesen-
teric resistance arteries and was limited to the usage of CsA. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Cyclosporine A (CsA) is a worldwide approved immu-
nosuppressive drug which is commonly used to prevent 
allograft rejection in human organ transplantation  [1] . 
Usage of CsA is often associated with the chronic devel-
opment of nephrotoxicity, graft failure and vascular dys-
function  [2, 3] . The mechanisms by which cyclosporine 
(CsA) causes vasculopathy after kidney transplantation 
are still under active scrutiny  [4] . Altered sympathetic ac-
tivity  [5] and modified peripheral vascular function  [6] 
are assumed mechanisms for the development of arterial 
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 Abstract 
 Usage of cyclosporine A (CsA) after kidney transplantation 
may be associated with development of nephrotoxicity and 
vasculopathy, but the mechanisms by which CsA causes vas-
cular dysfunction are still under scrutiny. We established a 
transplantation model and investigated the effect of CsA on 
vascular contractility with the aid of a pressurized myograph 
in comparison with control and unilaterally nephrectomized 
rats. Results were correlated with mRNA expression studies 
of   - and   -adrenoreceptors, in mesenteric resistance arter-
ies versus the thoracic aorta. Consequences of everolimus on 
functional properties as well as adrenoreceptor expression 
were also studied. CsA significantly downregulated expres-
sion of mesenteric adrenoreceptors, whereas no effect on 
aortic adrenoreceptors was seen. Administration of everoli-
mus had no influence on mRNA adrenoreceptor expression 
in mesenteric resistance arteries. Furthermore, contractile 
responses of mesenteric resistance arteries to norepineph-
rine were markedly reduced after treatment with CsA, while 
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hypertension in organ transplantation recipients treated 
with CsA. Thereby, CsA causes several pathophysiologi-
cal changes that have been regarded crucial for the side 
effects such as direct vasoconstriction  [7] , increased sym-
pathetic and angiotensin activities  [8, 9] , endothelin re-
lease  [10] as well as endothelin-mediated vasoconstric-
tion  [11] and altered renal metabolism of arachidonic acid 
favoring a vasoconstrictor prostanoid profile  [12] . Endo-
thelial dysfunction may also contribute to the side effects 
of CsA resulting in renal arterial vasoconstriction and 
subsequent nephrotoxicity  [13, 14] and hypertension  [15] . 
Vascular relaxation elicited by acetylcholine  [16] , brady-
kinin  [17] , substance P  [18] , calcium ionophore A23187 
 [17] , and prostaglandin E 1  [19] are remarkably impaired 
by CsA. Additionally, it was shown in uninephrecto-
mized rats that CsA significantly reduced renal blood 
flow, increased renal vascular resistance and that CsA-
mediated nephrotoxicity may in part be linked with the 
NO system  [20] .
 Due to the interfering data on the effect of CsA on the 
contractile properties of resistance arteries, we estab-
lished an experimental transplantation model in rats to 
enlighten this question  [21] .
 The experimental renal transplantation model with-
out concomitant medication and clinically approved CsA 
trough levels and a highly standardized protocol let us 
exclude interference from confounding factors as seen in 
human organ transplantation. We investigated the vas-
cular function of the mesenteric vascular bed with the aid 
of a pressurized myograph. To account for the impact
of immunological effects seen after allogenic transplan-
tation, we additionally studied unilaterally nephrecto-
mized rats treated with and without CsA, and control rats 
treated with and without CsA. Everolimus, as a calcineu-
rin-free immunosuppressive drug, was used as reference. 
Hypothesizing that CsA is driving its effects mainly in 
the endothelium of resistance arteries, we complemented 
these functional studies with mRNA expression studies 
of adrenergic   - and   -receptors in mesenteric resistance 
arteries versus the thoracic aorta to account for specific-
ity of resistance arteries.
 Materials and Methods 
 Animals/Experimental Renal Transplantation 
 Animal experiments were performed following the German 
law of animal protection and the NIH’s principles of laboratory 
animal care. Male Brown Norway rats serving as donors and Lew-
is rats serving as recipients (Charles River Laboratories, Sulzfeld, 
Germany) (200–250 g) were kept under a conventional housing 
and diet (KTx+CsA). The number and treatment regimens of the 
different groups are listed in  table 1 . Briefly, naive Lewis rats with 
and without CsA (ctrl 8 CsA) (CsA, 5 mg/kg b.w./day, liquid Ne-
oral; Novartis, Basel, Switzerland, administered once daily by ga-
vage) as well as unilaterally nephrectomized Lewis rats with and 
without CsA (UNx 8 CsA) served as controls. The rats were sac-
rificed 28 days after transplantation. Detailed protocols for per-
formance of renal transplantation have previously been published 
by our group  [22] . In brief, left kidneys were explanted, flushed 
with cold saline and transplanted orthotopically in Lewis recipi-
ents by end-to-end anastomosis of the vessels and, subsequently, 
the ureter of the donor and recipient. Cold and warm ischemia 
times were   35 and 30 min, respectively. Nephrectomy of the 
right kidney was performed at the end of surgery. After euthana-
sia, mesenteric arteries and aortae thoracicae were isolated as de-
scribed below. Naive Lewis rats treated with everolimus suspen-
sion according to the manufacturer’s instructions (ctrl+EVE) (1.5 
mg/kg b.w./day, administered once daily by gavage) served as cal-
cineurin inhibitor-free control group.
 In rats treated with CsA or everolimus, trough levels were 
measured by liquid chromatograph-mass spectrometry once a 
week.
 Renal Function and Histopathological Diagnoses 
 In the 28-day experimental protocol laboratory values and im-
munosuppression trough levels were studied on days 0, 7, 14, 21, 
and 28. The histopathological diagnoses according to the Banff 
97 classification  [23] of the kidney specimens were made by expe-
rienced pathologists.
Table 1. E xperimental renal transplantation model in rats in a 28-day protocol
Rat groups
Control
without
CsA
Control
with
CsA
Control
with
everolimus
Unilateral 
nephrectomized 
without CsA
Unilateral 
nephrectomized 
with CsA
Transplanted
with
CsA
Group abbreviation ctrl–CsA ctrl+CsA ctrl+EVE UNx–CsA Unx+CsA KTx+CsA
Number of rats, day 28 7 7 6 12 12 12
Histopathological classification, day 28 Banff 1 Banff 1 Banff 1 Banff 1 Banff 1 Banff 1 or Banff 4 IA
Serum creatinine 8 SD, day 28, mg/dl 0.280.01 0.2180.02 0.1980.06 0.3280.01 0.3580.01 0.3680.01
Immunosuppression trough levels, day 28, ng/ml not detected 202827.7 4.381.86 not detected 215829.6 171863.1
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 RNA Isolation, Reverse Transcription and Real-Time PCR in 
Rat Specimens 
 After homogenization of frozen tissue sections in peqGOLD 
TriFast (Peqlab, Erlangen, Germany) and additional sonication, 
total RNA was extracted according to the manufacturer’s in-
structions with additional DNase digestion to remove all traces 
of genomic DNA. Total RNA was reverse transcribed into cDNA 
according to standard protocols. In brief, cDNA probes were syn-
thesized in 20   l reaction volume with 1   g total RNA, 0.5   g 
oligo (dT) primer (Sigma-Aldrich, Munich, Germany), 40 units 
of RNasin (Promega, Mannheim, Germany), 0.5 m M dNTP (Am-
ersham, Freiburg, Germany), 4   l 5 ! transcription buffer and 
200 units of Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen, Karlsruhe, Germany) for 1 h at 37  °  C. In parallel, 
no-RT and no-template controls were performed. Real-time PCR 
was performed on a ABI PRISM 7900 detection system (Applied 
Biosystems, Darmstadt, Germany) using QuantiTect SYBR 
Green PCR Kit (Qiagen, Hilden, Germany). GAPDH was used as 
reference gene. All water controls were negative for target and 
housekeeper. The sequences of the used primers are listed in  ta-
ble 2 . 
 Preparation of Mesenteric Resistance Arteries 
 The intestines were exposed by a median incision of the abdo-
men and one segment of jejunum together with the mesenteric 
bed was quickly excised and placed in a dissection dish containing 
cold physiological salt solution. A 2- to 3-mm-long segment of 
third order branch of the superior mesenteric artery was care-
fully cleared from surrounding adipose tissue. After dissection 
the artery was transferred to the chamber of a pressure myograph 
(Danish Myo Technology  ) for cannulation. Suffusion and per-
fusion was performed using oxygenated 37  °  C Krebs solution (95% 
O 2 , 5% CO 2 ) containing (mM): NaCl 118, KCl 4.7, KH 2 PO 4 1.2, 
MgSO 4 1.2, CaCl 2 2.5, NaHCO 3 25, disodium EDTA 0.026, and 
glucose 11.0; pH 7.4. The vessel was mounted on two pipettes,
secured with suture and bubbled with 95% air and 5% CO 2 to 
achieve a pH of 7.4. The axial length of the vessel was adjusted by 
moving one cannula until the vessel walls were parallel without 
stretch. Vessels were equilibrated under a constant intraluminal 
pressure (45 mm Hg) for 1 h.
 Experimental Protocol 
 Experiments were performed under no-flow conditions. Vas-
cular reactivity was tested with norepinephrine (NE) (10 –5  M ). En-
dothelial function was pretested with acetylcholine (10 –4  M ). Con-
traction to NE was achieved with cumulative doses from 10 –8 to 
10 –4 M. Vascular reactivity was additionally assessed in response 
to cumulative doses of endothelin (10 –9 to 10 –6 M). The changes in 
internal diameter as well as media thickness of vessels in response 
to each increase in intravascular pressure was measured at three 
points along the vessel with use of a calibrated video system (Dan-
ish Myo Technology  ). Contraction to NE and endothelin was 
calculated as follows: (D r – D c )/D r   100, with D r as resting diam-
eter and D c as contracted diameter.
 Data Analysis 
 Data are presented as mean  8 SEM. Statistical analyses were 
performed using SigmaStat 3.0 software. Groups were compared 
using t test, one-way ANOVA, two-way ANOVA, or ANOVA for 
repeated measurements as appropriate. Post-hoc testing was 
performed using Bonferroni (two-way ANOVA) or Newman-
Keuls (one-way and repeated measures) test. p  ! 0.05 was sig-
nificant.
 Results 
 Characterization of the Different Groups 
 At day 28 there was almost no difference in serum cre-
atinine and histopathological diagnoses between the ex-
amined groups: in accordance with control and unilater-
ally nephrectomized rats, 10 out of 12 KTx+CsA rats 
showed normal histopathological classification (= Banff 
1), the other 2 rats showed only moderate signs of rejec-
tion (= Banff 4 IA) ( table 1 ). There were no differences in 
resulting renal function or measured CsA trough levels 
( table 1 ). Everolimus-treated rats matched the CsA-treat-
ed rats in matters of resulting serum creatinine and Banff 
classification. The abbreviations, numbers, treatment 
regimens, histopathological diagnosis, and data corre-
sponding to the renal function of the different groups of 
rats are summarized in  table 1 .
Table 2. P rimers of the in vivo experiment
Gene Forward primer Reverse primer
GAPDH 5-gtcgtggatctgacgtgcc-3 5-gatgcctgcttcaccacctt-3
rADra1 5-gaatgtcctgcgaatccagt-3 5-gggatacgcaccatgtctct-3
rADra1 5-cctgaggatccactccaaga-3 5-cgactacaatgcccaaggtt-3
rADra1 5-ccgaggtagaagcagtgtcc-3 5-gtcagtctctcggaggttgc-3
rADrab1 5-acgctcaccaacctcttcat-3 5-cgtctaccgaagtccagagc-3
rADrab2 5-caggcctatgctatcgcttc-3 5-tgccctcggatttgtctatc-3
rADrab3 5-cgcaccttgggtctcattat-3 5-gaaggcagagttggcatagc-3
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 mRNA Expression of Mesenteric   1 - and   -Adrenergic 
Receptors (ADRs) 
 Administration of CsA did not significantly influence 
mRNA expression of mesenteric   1 - (subtypes a, b, d) and 
  -ADRs (subtypes 1, 2, 3) in a day 6 protocol (data not 
shown).
 In the day 28 protocol, administration of CsA signifi-
cantly downregulated expression of mesenteric   1 -ADRs. 
The   1 -subtype a ADR was significantly downregulated 
in the ctrl+CsA group (p = 0.05) as well as in the unilater-
ally nephrectomized group (UNx+CsA) (p = 0.05) and 
the transplanted group (KTx+CsA) (p = 0.003) ( fig. 1 a). 
In accordance with   1 -subtype a,   1 -subtype b was also 
significantly downregulated in the identical groups 
(ctrl+CsA p = 0.04, UNx+CsA p = 0.01, KTx+CsA p = 
0.003). mRNA expression of subtype d of mesenteric   1 -
ADRs was only significantly downregulated in trans-
planted rats (p = 0.01) ( fig. 1 a).
 mRNA expression of   1 -ADR was not significantly 
downregulated after 28 days of CsA administration. 
There was only a trend for downregulation in the unilat-
erally nephrectomized as well as the transplanted rats 
( fig. 1 b). mRNA expression of   2 -ADR was significantly 
downregulated in all three CsA-treated groups (ctrl+CsA 
p = 0.05, UNx+CsA p = 0.0004, KTx+CsA p = 0.03) 
( fig. 1 b). In accordance with   2 -ADR,   3 -ADR was also 
significantly downregulated after administration of CsA 
in these groups (ctrl+CsA p = 0.03, UNx+CsA p = 0.003, 
KTx+CsA p = 0.006) ( fig. 1 b).
 mRNA expression of   1 -(subtypes a, b, d) and   -ADRs 
(subtypes 1, 2, 3) was neither significantly influenced af-
ter 6 (data not shown) nor 28 days in thoracic aorta (fig. 
2a). Additionally, administration of everolimus had no 
influence on mRNA expression of   1 - (subtypes a, b, d) 
and   -ADRs (subtypes 1, 2, 3) in mesenteric resistance 
arteries ( fig. 2 b) as well as the thoracic aorta in control 
rats in the 28-day protocol (data not shown).
 Contractility of Mesenteric Arteries 
 Contractile responses of mesenteric resistance arteries 
to NE were markedly reduced after treatment with CsA 
in control rats (ctrl+CsA p  ! 0.05 for maximal stimula-
tion;  fig.  3 ) and unilaterally nephrectomized rats 
(UNx+CsA p  ! 0.05;  fig. 4 ). In transplanted rats treated 
with CsA, the response to NE was diminished compared 
to UNx+CsA rats ( fig. 4 ). Contractile responses to endo-
thelin were identical in all groups ( fig.  5 ). In contrast, 
everolimus did not alter the contractility response to NE 
in control rats ( fig. 3 ).
 Discussion 
 In our experimental model the effect of CsA on vascu-
lar contractility in mesenteric resistance arteries was 
studied on a pressurized myograph. Additionally, these 
results have been completed by mRNA analyses of   1 -a-, 
b-, d- and   -adrenoreceptors. We were able to demon-
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 Fig. 1. mRNA expression of mesenteric   1 - and   -ADRs.  a mRNA 
expression of mesenteric   1 (subtypes a, b, d) receptors after 28 
days of CsA treatment in the different experimental groups: con-
trol rats with/without CsA (ctrl 8 CsA), unilaterally nephrecto-
mized rats with/without CsA (UNx 8 CsA) and transplanted rats 
with CsA (KTx+CsA). # p  ! 0.05 was regarded as statistically sig-
nificant.  b mRNA expression of   1 -,   2 -, and   3 -mesenteric ad-
renoreceptors in the different experimental groups: control rats 
with/without CsA (ctrl 8 CsA), unilaterally nephrectomized rats 
with/without CsA (UNx 8 CsA) and transplanted rats with CsA 
(KTx+CsA).  #  p  ! 0.05 was regarded as statistically significant. 
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strate that NE-induced, but not endothelin-induced, con-
tractile responses of mesenteric resistance arteries are 
blunted in CsA-treated rats after 28 days. Detected find-
ings were limited on the usage of CsA and could not been 
demonstrated using everolimus, a calcineurin inhibitor-
free immunosuppression. The findings may be caused by 
the significant downregulation of   1 -b-,   1 -d-,   2 - and 
  3 -adrenoreceptors in mesenteric resistance arteries, 
whereas mRNA expression of any investigated   - and   -
ADR was not significantly altered in the thoracic aorta. 
Our data are in accordance with functional studies show-
ing that vascular contractility is decreased in mesenteric 
resistance arteries in response to NE after CsA treatment 
 [24] . In contrast to other experimental data with unphys-
iologically high doses of CsA, we were able to show that 
the usage of CsA with clinical approved trough levels  [25] 
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 Fig. 2. mRNA expression of aortic ADRs and effect of everolimus 
in control rats.  a mRNA expression of aortic   1 - (subtypes a, b, d) 
and   1 -,   2 -, and   3 -ADRs after 28 days of CsA treatment in con-
trol rats with/without CsA (ctrl 8 CsA). p  ! 0.05 was regarded as 
statistically significant.  b Effect of everolimus on mRNA expres-
sion of mesenteric   1 - (subtypes a, b, d) and   1 -,   2 -, and   3 -ADRs 
in control rats treated with/without everolimus (ctrl 8 EVE) for 28 
days.  #  p  ! 0.05 was regarded as statistically significant. 
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 Fig. 4. Contraction of mesenteric resistance arteries under stimu-
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mized rats treated with/without CsA (UNx–CsA, UNx+CsA) for 
28 days and transplanted rats treated with CsA (KTx+CsA).  *  p  ! 
0.05 was regarded as statistically significant. 
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not only altered vascular contractility but also maximum 
contraction in response to NE. These effects were dem-
onstrated after 28 days of CsA treatment and are in ac-
cordance with data on the endothelial and vascular 
smooth muscle function after 3 weeks of CsA treatment 
 [26] . We have to state that the observed differences were 
seen predominantly with supraphysiologic doses. Never-
theless, this illustrates a general hyporesponsiveness to 
NE. The influence of CsA only on resistance arteries un-
derlines the physiological relevance of the detected re-
sults due to a well-known fact that these vessels are the 
main target of endothelial dysfunction. Besides mesen-
teric resistance arteries, renal resistance arteries may also 
be affected and this may in part contribute to CsA-in-
duced nephrotoxicity and renal vasculopathy. However, 
our results are to some degree inconsistent with findings 
that postulated that resistance vessels obtained from 
transplanted kidneys were more sensitive to NE  [27] . The 
findings of a decreased sensitivity to noradrenaline are in 
contrast to previous reports of an enhanced vascular sen-
sitivity to adrenergic agonists in the presence of CsA: in-
tramuscular administration of surplus doses of CsA (20 
mg/kg/day) for 7 days enhanced vasoconstriction in re-
sponse to noradrenaline  [28] . Hence these results have 
been demonstrated not in resistance but large vessels. In 
accordance, Tavares et al.  [29] postulated an increased 
catecholamine release from the sympathic nervous end-
ings of rat aorta after CsA treatment for 7 weeks with 
surplus doses of CsA (30 mg/kg/day). Therefore, the im-
portance of examined vessel size as already previously 
discussed  [30, 31] is crucial for the detected results and 
may explain the differences between our findings and 
previous reports  [32–34] which focused on aortic but not 
mesenteric arteries. Apart from the studied vessel size, 
detected results depend on the used dosage of CsA, e.g. 
subcutaneous administration of almost nephrotoxic dos-
ages of CsA (60 mg/kg/day) for 5 days caused enhanced 
vasoconstriction induced by NE  [35] and also increased 
catecholamine release (30 mg CsA/mg  kg  [29] ). Thus, 
clinically approved CsA trough levels as used in our ex-
perimental model may cause effects totally different from 
those caused by almost toxic CsA doses. The reduced re-
sponse to noradrenaline by mesenteric arteries may be 
even regarded as an escape mechanism for the CsA side 
effects.
 Looking for the underlying pathophysiological mech-
anisms, we focused on mRNA expression of   - and   -
ADRs. The existence of   -adrenoceptors in rat aorta  [36, 
37] as well as in rat mesenteric resistance arteries  [38] was 
shown previously by several groups. An interaction of   1 -
adrenoreceptors under exposure to CsA has already been 
described  [39] and Tavares et al.  [37] also detected a sig-
nificant downregulation of   -adrenoreceptor expression 
after CsA treatment. In contrast, in our study the expres-
sion level of   -adrenoreceptors was only significantly 
downregulated in the mesenteric resistance arteries, 
whereas it remained unchanged in the aorta. In accor-
dance with the functional data, detected findings were 
limited on the usage of CsA and could not be demon-
strated using everolimus, neither in the thoracic aorta nor 
in mesenteric arteries. These findings underline the 
physiological relevance of our data since resistance ves-
sels are believed to be crucial in peripheral control of vas-
culopathy and systemic blood pressure  [40] . The down-
regulation of   1 -adrenoceptors may to some degree be 
caused by modified activation of protein kinase C  [37] as 
well as by structural damage and modified vessel archi-
tecture  [41] .
 To distinguish if reduced response to NE-induced 
contractile response was only caused by modified   1 ex-
pression, we also investigated the expression of   1 -,   2 - 
and   3 -adrenoreceptors after CsA treatment in mesen-
teric resistance arteries as well as in the thoracic aorta. 
The presence of these receptors in these vessel regions has 
been described previously  [42, 43] . It has been shown that 
CsA treatment provokes a downregulation of   1 cardiac 
adrenoreceptors  [33] as well as a downregulation of   -
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ADRs in bovine pulmonary artery smooth muscle cells 
 [44] . In accordance with these studies, we could see a 
marked downregulation of all   2 - and   3 -adrenoreceptor 
subtypes under CsA therapy in mesenteric resistance ar-
teries, but not in the thoracic aorta. The additional down-
regulation of   2 - and   3 -adrenoreceptors in our study in 
contrast to previous work  [33] may be caused by the dif-
ferent time course of CsA treatment (28 days vs. 6 weeks), 
the different dosages that were used and the differences 
of the vessel region investigated. In future the conse-
quences of CsA on specific   -/  -adrenoreceptor expres-
sion in comparison with specific   - or   -adrenoreceptor 
blockers have to be examined. Whether CsA directly re-
duces blood flow and increases vascular resistance or 
whether altered serum concentration of NO or the delete-
rious toxic effects of CsA due to increased production of 
free radicals and ROS  [45] effect detected results, remains 
unresolved. However, as renal vessels are resistance ves-
sels comparable with mesenteric resistance arteries, the 
detected results during CsA treatment may be regarded 
as surrogate of CsA-mediated renal vasculopathy.
 However, in contrast to Takeda et al.  [46, 47] , who re-
ported that CsA increased endothelin production and en-
dothelin mRNA levels in rat mesenteric arteries, we did 
not observe any effects on endothelin-mediated contrac-
tion in CsA-treated rats. The effects having been found in 
the experimental protocol by Takeda et al. may have been 
caused by surplus doses of CsA (25 mg/kg/day).
 In summary, we found that NE-induced, but not en-
dothelin-induced, contractile responses of mesenteric re-
sistance arteries are blunted in CsA-treated rats, even 
with clinically approved CsA trough levels. This finding 
was accompanied by a marked downregulation of   - and 
  -adrenoreceptors in mesenteric resistance arteries, but 
not in the thoracic aorta. Our findings were also limited 
to the usage of CsA, whereas everolimus neither induced 
functional changes nor modified adrenoreceptor expres-
sion.
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